The TaMADOR program was funded with cooperative agreements between the NIDDK and consortium institutions a few years ago, and will now continue with emphasis on the development of assays of importance in type 1 diabetes clinical research.

See the NIH Request for Applications (RFA-DK-21-031).

The Principal Investigators leading this effort on type 1 diabetes are:

  • Dr. Andrew Hoofnagle (University of Washington, Seattle)
  • Dr. Michael MacCoss (University of Washington, Seattle)
  • Dr. Jun Qu (University at Buffalo)
  • Dr. Weijun Qian (PNNL)

Within the RFA we indicated a list of potential targets that the group could be working on, including:

  • Glucagon and other pro-glucagon derived peptides
  • C-peptide
  • Insulin
  • Pro-insulin
  • Glycated CD59
  • Islet Amyloid Polypeptide (IAPP)
  • Chromogranin A (CgA)
  • Chromogranin B (CgB)

We are looking forward to advisory group and community feedback for determining consortium priorities.